34,426
Views
758
CrossRef citations to date
0
Altmetric
Articles

Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors

, , , , , , , , , , , , & ORCID Icon show all
Pages 1123-1130 | Received 16 Mar 2020, Accepted 11 May 2020, Published online: 31 May 2020

References

  • Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 Feb 24. doi:10.1016/s2213-2600(20)30079-5.
  • Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020 Feb 18. doi:10.1016/s2213-2600(20)30076-x.
  • Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect. 2020 Feb 22. doi:10.1016/j.micinf.2020.02.006.
  • Gu Y, Hsu AC, Pang Z, et al. Role of the innate cytokine storm induced by the influenza A virus. Viral Immunol. 2019 Jul/Aug;32(6):244–251. doi:10.1089/vim.2019.0032.
  • Ferrero-Miliani L, Nielsen OH, Andersen PS, et al. Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation. Clin Exp Immunol. 2007 Feb;147(2):227–235. doi:10.1111/j.1365-2249.2006.03261.x.
  • Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev. 2009 Jan;227(1):75–86. doi:10.1111/j.1600-065X.2008.00737.x.
  • Lin L, Li TS. Interpretation of “guidelines for the diagnosis and treatment of novel coronavirus (2019-nCoV) infection by the National Health Commission (Trial Version 5)”. Zhonghua Yi Xue Za Zhi. 2020 Feb 7;100(0):E001. doi:10.3760/cma.j.issn.0376-2491.2020.0001.
  • Zu ZY, Jiang MD, Xu PP, et al. Coronavirus disease 2019 (COVID-19): a perspective from China. Radiology. 2020 Feb 21:200490. doi:10.1148/radiol.2020200490.
  • Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020 Feb 6;7(1):4. doi:10.1186/s40779-020-0233-6.
  • Diagnosis and clinical management of 2019 novel coronavirus infection: an operational recommendation of Peking Union Medical College Hospital (V2.0). Zhonghua Nei Ke Za Zhi. 2020 Feb 4;59(3):186–188. doi:10.3760/cma.j.issn.0578-1426.2020.03.003.
  • Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-Infected pneumonia in Wuhan, China. JAMA. 2020 Feb 7. doi:10.1001/jama.2020.1585.
  • Zhang J, Zhou L, Yang Y, et al. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet Respir Med. 2020 Mar;8(3):e11–e12. doi:10.1016/s2213-2600(20)30071-0.
  • Chen L, Liu HG, Liu W, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 6;43(0):E005. doi:10.3760/cma.j.issn.1001-0939.2020.0005.
  • Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020 Mar;63(3):364–374. doi:10.1007/s11427-020-1643-8.
  • The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 17;41(2):145–151. doi:10.3760/cma.j.issn.0254-6450.2020.02.003.
  • Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497–506. doi:10.1016/s0140-6736(20)30183-5.
  • Hui DSC, Zumla A. Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Infect Dis Clin North Am. 2019 Dec;33(4):869–889. doi:10.1016/j.idc.2019.07.001.
  • Azhar EI, Hui DSC, Memish ZA, et al. The Middle East respiratory syndrome (MERS). Infect Dis Clin North Am. 2019 Dec;33(4):891–905. doi:10.1016/j.idc.2019.08.001.
  • Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020 Apr;92(4):424–432. doi:10.1002/jmv.25685.
  • Gadient RA, Patterson PH. Leukemia inhibitory factor, Interleukin 6, and other cytokines using the GP130 transducing receptor: roles in inflammation and injury. Stem Cells. 1999;17(3):127–137. doi:10.1002/stem.170127.
  • McKinstry KK, Strutt TM, Buck A, et al. IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge. J Immunol. 2009 Jun 15;182(12):7353–7363. doi:10.4049/jimmunol.0900657.
  • Fattori E, Cappelletti M, Costa P, et al. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med. 1994 Oct 1;180(4):1243–1250. doi:10.1084/jem.180.4.1243.
  • Stuber F, Wrigge H, Schroeder S, et al. Kinetic and reversibility of mechanical ventilation-associated pulmonary and systemic inflammatory response in patients with acute lung injury. Intensive Care Med. 2002 Jul;28(7):834–841. doi:10.1007/s00134-002-1321-7.
  • Parsons PE, Eisner MD, Thompson BT, et al. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med. 2005 Jan;33(1):1–6; discussion 230-2. doi:10.1097/01.ccm.0000149854.61192.dc.
  • Kim GW, Lee NR, Pi RH, et al. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. Arch Pharm Res. 2015;38(5):575–584. doi:10.1007/s12272-015-0569-8.
  • Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol. 2019 Aug;15(8):813–822. doi:10.1080/1744666x.2019.1629904.